Pembrolizumab alone or with chemotherapy for recurrent/metastatic had and neck squamous cell carcinoma in KEYNOTE-048: subgroup analysis by programmed death Ligand-1 combined positive score (2022)
- Authors:
- Autor USP: CASTRO JUNIOR, GILBERTO DE - FM
- Unidade: FM
- DOI: 10.1200/JCO.21.02198
- Subjects: NEOPLASIAS DE CABEÇA E PESCOÇO; QUIMIOTERAPIA; CARCINOMA DE CÉLULAS ESCAMOSAS; METÁSTASE NEOPLÁSICA
- Agências de fomento:
- Language: Inglês
- Imprenta:
- Publisher place: Philadelphia
- Date published: 2022
- Source:
- Título: Journal of clinical oncology
- ISSN: 0732-183X
- Volume/Número/Paginação/Ano: v. 40, n. 21, p. 2321-2334, 2022
- Este periódico é de assinatura
- Este artigo é de acesso aberto
- URL de acesso aberto
- Cor do Acesso Aberto: hybrid
- Licença: cc-by-nc-nd
-
ABNT
BURTNESS, Barbara et al. Pembrolizumab alone or with chemotherapy for recurrent/metastatic had and neck squamous cell carcinoma in KEYNOTE-048: subgroup analysis by programmed death Ligand-1 combined positive score. Journal of clinical oncology, v. 40, n. 21, p. 2321-2334, 2022Tradução . . Disponível em: https://doi.org/10.1200/JCO.21.02198. Acesso em: 04 out. 2024. -
APA
Burtness, B., Rischin, D., Greil, R., Soulieres, D., Tahara, M., Castro Junior, G. de C., et al. (2022). Pembrolizumab alone or with chemotherapy for recurrent/metastatic had and neck squamous cell carcinoma in KEYNOTE-048: subgroup analysis by programmed death Ligand-1 combined positive score. Journal of clinical oncology, 40( 21), 2321-2334. doi:10.1200/JCO.21.02198 -
NLM
Burtness B, Rischin D, Greil R, Soulieres D, Tahara M, Castro Junior G de C, Psyrri A, Brana I, Baste N, Neupane P. Pembrolizumab alone or with chemotherapy for recurrent/metastatic had and neck squamous cell carcinoma in KEYNOTE-048: subgroup analysis by programmed death Ligand-1 combined positive score [Internet]. Journal of clinical oncology. 2022 ; 40( 21): 2321-2334.[citado 2024 out. 04 ] Available from: https://doi.org/10.1200/JCO.21.02198 -
Vancouver
Burtness B, Rischin D, Greil R, Soulieres D, Tahara M, Castro Junior G de C, Psyrri A, Brana I, Baste N, Neupane P. Pembrolizumab alone or with chemotherapy for recurrent/metastatic had and neck squamous cell carcinoma in KEYNOTE-048: subgroup analysis by programmed death Ligand-1 combined positive score [Internet]. Journal of clinical oncology. 2022 ; 40( 21): 2321-2334.[citado 2024 out. 04 ] Available from: https://doi.org/10.1200/JCO.21.02198 - Diagnóstico de mutações ativadoras do gene EGFR em adenocarcinomas pulmonares: caracterização e implicações clínicas
- Efficacy and safety of ceritinib (450 mg/d or 600 mg/d) with food versus 750-mg/d fasted in patients with ALK receptor tyrosine kinase (ALK)-Positive NSCLC: primary efficacy results from the ASCEND-8 study
- Extraoral photobiomodulation for prevention of oral and oropharyngeal mucositis in head and neck cancer patients: interim analysis of a randomized, double-blind, clinical trial
- Manual de oncologia torácica
- Lung Cancer in Brazil [Editorial]
- Pembrolizumab alone or with chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: health-related quality-of-life results from KEYNOTE-048
- Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
- Noções de oncologia torácica
- Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study
- Oral vinorelbine and cisplatin as first-line therapy for advanced squamous NSCLC patients: a prospective randomized international phase II study (NAVoTrial 03)
Informações sobre o DOI: 10.1200/JCO.21.02198 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
